Niraparib

Target: This ligand targets poly(ADP-ribose) polymerases PARP1 and PARP2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for poly(ADP-ribose) polymerases PARP1 and PARP2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings poly(ADP-ribose) polymerases PARP1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PARP1-PROTAC Degradation Strategy: Niraparib can serve as a PARP1-binding ligand within PROTAC designs to recruit an E3 ligase and drive ubiquitin-mediated degradation of PARP1. This application supports studies of how complete PARP1 removal, rather than catalytic inhibition alone, reshapes DNA damage response signaling, repair pathway choice, and PARP1-dependent cellular phenotypes.

• DNA Damage Response Modulation: Using Niraparib-based PROTACs enables targeted degradation of PARP1 to dissect downstream effects on replication stress, single-strand break repair, and PARP1-dependent recruitment of repair factors. Researchers can compare degradation-driven pathway changes against inhibitor-only controls to identify mechanisms that govern survival under genotoxic stress.

• E3 Ligase Recruitment Optimization: Niraparib can be incorporated into PROTAC scaffolds to systematically evaluate different E3 ligase recruiters and linker architectures. This direction is relevant for mapping how ligase selection and spatial constraints influence ternary complex formation, degradation kinetics, and selectivity across PARP family members.

• Mechanistic Studies of PARP Dependency: Niraparib-based targeted protein degradation tools can clarify whether observed PARP1-associated effects are driven by enzymatic activity, protein scaffolding functions, or both. By monitoring PARP1 turnover and correlating it with transcriptional and repair readouts, researchers can define PARP1 dependency at molecular and pathway levels.

Niraparib is a PARP target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Niraparib is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.